nimodipine has been researched along with Inflammatory Response Syndrome, Systemic in 1 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 1 |
| Ma, H | 1 |
| Huang, J | 1 |
| Yao, Z | 1 |
| Yu, J | 1 |
| Zhang, W | 1 |
| Zhang, L | 1 |
| Wang, Z | 1 |
| Zhuang, C | 1 |
1 other study available for nimodipine and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors.
Topics: Administration, Oral; Animals; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Dru | 2021 |